Atilla Erden, Atilla Pinar Ataca, Bozdag Sinem Civriz, Yuksel Meltem Kurt, Toprak Selami Kocak, Topcuoglu Pervin, Akay Bengu Nisa, Sanli Hatice, Gurman Gunhan, Ozcan Muhit
BMT Unit, Department of Hematology, Cebeci Hospital, School of Medicine, Ankara University, Dikimevi, 06590, Ankara, Turkey.
Department of Dermatology, School of Medicine, Ankara University, Ankara, Turkey.
Int J Hematol. 2017 Sep;106(3):426-430. doi: 10.1007/s12185-017-2245-x. Epub 2017 May 2.
Cutaneous T cell lymphoma is a heterogeneous group of lymphoproliferative disorders with different clinical behavior and prognosis in which malignant T cells accumulate in the skin. In the relapsed/refractory stage, treatment strategy varies depending on clinical perspective. We retrospectively evaluated advanced stage relapse or refractory mycosis fungoides and Sezary syndrome patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our hospital. The overall response rate was 25%, while the disease progressed and relapsed after transplant in 38% of patients. Allo-HSCT may be a reasonable treatment option in the relapsed/refractory stage.
皮肤T细胞淋巴瘤是一组异质性的淋巴增殖性疾病,具有不同的临床行为和预后,其中恶性T细胞在皮肤中积聚。在复发/难治阶段,治疗策略因临床情况而异。我们回顾性评估了在我院接受异基因造血干细胞移植(allo-HSCT)的晚期复发或难治性蕈样肉芽肿和 Sézary 综合征患者。总缓解率为25%,而38%的患者在移植后疾病进展和复发。allo-HSCT可能是复发/难治阶段的一种合理治疗选择。